Vanderbilt researchers have identified cancer cell-specific genetic alterations that reprogram the immune “landscape,” thereby driving tumor growth, and discovered a potential new drug target for stopping it.

In a national retrospective study led by researchers at Vanderbilt University School of Medicine, diltiazem, when given in combination with the anticoagulant drugs apixaban (Eliquis) or rivaroxaban (Xarelto), significantly increased the risk of serious bleeding compared to metoprolol.

Coronary artery disease and major depression may be genetically linked via inflammatory pathways to an increased risk for cardiomyopathy, a degenerative heart muscle disease, researchers at Vanderbilt University Medical Center and Massachusetts General Hospital have found.

Excessive consumption of dietary sodium likely was responsible for up to 30% of cardiovascular disease-related deaths among mostly low-income participants in a large cohort study conducted by Vanderbilt University Medical Center.

Laboratory and administrative personnel at Vanderbilt University Medical Center were honored on March 29 for research excellence during the 20th annual Research Staff Awards Ceremony.

An international research team co-led by Vanderbilt University Medical Center has revealed how variations in gene regulation in different cell types drive pulmonary fibrosis, a progressive respiratory disorder characterized by scarring and loss of functional lung tissue.